title: Hypothalamic arousal regions are activated during modafinil-induced wakefulness.
abstract: Modafinil is an increasingly popular wake-promoting drug used for the treatment of narcolepsy, but its precise mechanism of action is unknown. To determine potential pathways via which modafinil acts, we administered a range of doses of modafinil to rats, recorded sleep/wake activity, and studied the pattern of neuronal activation using Fos immunohistochemistry. To contrast modafinil-induced wakefulness with spontaneous wakefulness, we administered modafinil at midnight, during the normal waking period of rats. To determine the influence of circadian phase or ambient light, we also injected modafinil at noon on a normal light/dark cycle or in constant darkness. We found that 75 mg/kg modafinil increased Fos immunoreactivity in the tuberomammillary nucleus (TMN) and in orexin (hypocretin) neurons of the perifornical area, two cell groups implicated in the regulation of wakefulness. This low dose of modafinil also increased the number of Fos-immunoreactive (Fos-IR) neurons in the lateral subdivision of the central nucleus of the amygdala. Higher doses increased the number of Fos-IR neurons in the striatum and cingulate cortex. In contrast to previous studies, modafinil did not produce statistically significant increases in Fos expression in either the suprachiasmatic nucleus or the anterior hypothalamic area. These observations suggest that modafinil may promote waking via activation of TMN and orexin neurons, two regions implicated in the promotion of normal wakefulness. Selective pharmacological activation of these hypothalamic regions may represent a novel approach to inducing wakefulness.
authors.affiliation: Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA. tscammel@caregroup.harvard.edu
authors.forename: T E
authors.initials: TE
authors.lastname: Scammell
authors.forename: I V
authors.initials: IV
authors.lastname: Estabrooke
authors.forename: M T
authors.initials: MT
authors.lastname: McCarthy
authors.forename: R M
authors.initials: RM
authors.lastname: Chemelli
authors.forename: M
authors.initials: M
authors.lastname: Yanagisawa
authors.forename: M S
authors.initials: MS
authors.lastname: Miller
authors.forename: C B
authors.initials: CB
authors.lastname: Saper
mesh_terms: D000818:Animals; D001143:Arousal / Q000187:drug effects* / Q000502:physiology; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D002940:Circadian Rhythm / Q000502:physiology; D003624:Darkness; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D007031:Hypothalamus / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D007150:Immunohistochemistry; D008027:Light; D000077408:Modafinil; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D014851:Wakefulness / Q000187:drug effects* / Q000502:physiology
chemical_list: D001559:Benzhydryl Compounds; D016760:Proto-Oncogene Proteins c-fos; D000077408:Modafinil